Anti-leukemic and immunomodulatory effects of fungal metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats by Olufemi, Akanni E. et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
VOLUME 47ㆍ NUMBER 1ㆍ March 2012
THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE
Anti-leukemic and immunomodulatory effects of fungal 
metabolites of Pleurotus pulmonarius and Pleurotus ostreatus on 
benzene-induced leukemia in Wister rats
Akanni E. Olufemi
1, Alli O.A. Terry
2, Oloke J. Kola
3
1Hematology Division, Department of Biomedical Science, College of Health Sciences, Departments of  
2Biomedical Science, 
3Pure and 
Applied Biology, Ladoke Akintola University of Technology, Osogbo, Nigeria
p-ISSN 1738-7949 / e-ISSN 2092-9129
http://dx.doi.org/10.5045/kjh.2012.47.1.67
Korean J Hematol 2012;47:67-73.
Received on August 10, 2011
Revised on February 21, 2012
Accepted on March 2, 2012
Background
The use of natural bioactive compounds in conventional chemotherapy is a new direction 
in cancer treatment that is gaining more research attention recently. Bioactive poly-
saccharides and polysaccharide-protein complexes from some fungi (edible mushrooms) 
have been identified as sources of effective and non-toxic antineoplastic agents. Selected 
oyster mushrooms (Pleurotus pulmonarius and P. ostreatus being local [Nigeria] and exot-
ic strains, respectively) were cultured on a novel medium of yeast extract supplemented 
with an ethanolic extract of Annona senegalensis, and the antileukemic potential of their 
metabolites was studied. 
Methods
Leukemia was successfully induced in Wister rats by intravenous injection (0.2 mL) of 
a benzene solution every 2 days for 3 consecutive weeks. The aqueous solution of fungal 
metabolites (20 mg/mL) produced by submerged fermentation was orally administered 
(0.2 mL) before, during, and after leukemia induction. Leukemia burden was assessed 
by comparing the hematological parameters at baseline and after leukemia induction. The 
immunomodulatory potential of the metabolites was assessed by using a phagocytic as-
say (carbon clearance method). The ability to enhance leukopoiesis was assessed by using 
the total leukocyte count.
Results
Leukemia induction resulted in significant anemia indices and leukocytosis (P＜0.05) in 
the experimental rats. Both metabolites equally enhanced leukopoiesis and demon-
strated phagocytic actions; P. ostreatus activity was significantly higher than that of P. pul-
monarius (P＜0.05). 
Conclusion
The metabolites exhibited profound antileukemic potential by suppressing leukemia and 
demonstrating immunotherapeutic activities on animals after oral administration in vari-
ous experimental groups. 
Key Words Anti-leukemic, Pleurotus pulmonarius and P. ostreatus metabolites, 
Immunotherapy, Polysaccharide-protein complexes
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INTRODUCTION
The global awareness of leukemia as one of the major 
causes of cancer death worldwide in people of various ages 
and racial background has led to intensive research efforts 
and numerous clinical studies in the fight against the disease 
[1]. Leukemia, a cancer of the blood or bone marrow, is 
characterized by an abnormal increase in blood cells, usually 
leukocytes, which results from somatic mutations in the 
DNA. Certain mutations produce leukemia by activating on-
cogenes or deactivating tumor suppressor genes, thereby dis-
rupting the regulation of cell death, differentiation, or 
division. These mutations may occur spontaneously or after Korean J Hematol 2012;47:67-73.
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Table 1. Experimental protocol for antileukemic testing of the metabolites.
Group Treatment Interference
A Leukemia induction+METAB administration (simultaneously) Chemo preventive
B Leukemia induction 2 weeks pre-METAB treatment Chemotherapeutic
C METAB administration 2 weeks prior to leukemia induction Leukemia suppressor
D METAB administration+commercial diet only Adverse reaction/toxicity
E Leukemia induction+placebo Leukemia control
F Control (commercial feed+water) Reference values
All treatments were replicated and appropriately controlled. Sterile water was used as placebo.
Abbreviation: METAB, metabolites of P. pulmonarius or P. ostreatus.
exposure to radiation or carcinogenic substances and are 
likely to be influenced by genetic factors [2].
Currently, researchers are focusing on organisms that ap-
pear to offer anti-cancer and immune system enhancing 
activity. Depending on the stage of cancer progression, treat-
ments include surgical operation, radiotherapy, and chemo-
therapy. Most cancer chemotherapies are essentially toxic, 
because it is difficult to apply the principle of selective tox-
icity used in the treatment of microbial infections. Patients 
receiving these agents experience severe side effects that 
limit the doses which can be administered, and hence, limit 
the beneficial effects. Clinical investigators realized that the 
ability to manage these toxicities is crucial to the success 
of cancer chemotherapy. However, their side effects cause 
serious damage and negatively affect the patients. As an 
alternative to these treatment methods, immunotherapy is 
now gaining more attention than ever. Immunotherapy sub-
stantially reduces the side effects and the inherent pain of 
cancer experienced by patients and helps to overcome cancer 
growth, even in the last stages of the disease [3].
Recent investigations have been channeled on the devel-
opment of immunotherapies to target and remove cancer 
cells as well as on substances such as immunopotentiators, 
immunoinitiators, and biological response modulators that 
act to prevent carcinogenesis and induce carcinostasis [1].
Some polysaccharides or polysaccharide-protein com-
plexes from mushrooms (fungi) are able to stimulate the 
non-specific immune system and exert antitumor activities 
through stimulation of the host’s defense mechanism [4]. 
These substances activate effector cells such as macrophages, 
T lymphocytes, and natural killer (NK) cells to secrete cyto-
kines, e.g., tumor necrosis factor (TNF)-α, interferon (IFN)-γ, 
interleukin (IL)-1β, etc., which are anti-proliferative and 
induce apoptosis and differentiation in tumor cells. Pleurotus 
ostreatus and P. pulmonarius are edible mushrooms possess-
ing biological activities related to immune enhancement and 
in vitro anticancer effects [3].
This work aimed at determining the antileukemic action 
of metabolites from P. pulmonarius, a local strain, and P. 
ostreatus, an exotic strain, and comparing their potentials.
MATERIALS AND METHODS
1. Production of the metabolites
P. pulmonarius and P. ostreatus metabolites were produced 
by submerged fermentation at the Biotechnology Laboratory 
of Ladoke Akintola University of Technology, Ogbomoso, 
Nigeria. P. pulmonarius and P. ostreatus were cultured/fer-
mented in standard yeast extract-glucose medium supple-
mented with 5 g/L ethanolic extract of Annona senegalensis. 
The yeast extract-glucose medium consisted of: glucose 50 g/L, 
peptone 2.5 g/L, yeast extract 2.5 g/L, KH2PO4 2 g/L, 
MgSO4.7H2O 1 g/L, and CaCl2.2H2O 1 g/L; the pH was main-
tained at 5.8. The fungi were inoculated into separate fermen-
tation flasks by using 3 agar plugs each (6 mm diameter) 
from the outer circumference of a fungal colony growing 
on a potato dextrose agar medium plate. This served as the 
inoculum [5]. The media were then incubated on an orbital 
shaker at 28
oC for 7 days at 150 rpm. The medium was 
harvested after 7 days of fermentation by using a cheesecloth 
to sieve in order to obtain the mycelia mass. The filtrate 
was measured by using a measuring cylinder and an equal 
volume of acetone was added to precipitate the metabolites. 
The broth was filtered with filter paper to remove the 
metabolites. The concentration of the metabolite solutions 
was adjusted to 20 mg/mL.
2. Administration of metabolites
The rats were administered 0.2 mL of the metabolite sol-
ution by gavage daily before, during, and after leukemia 
induction as designed in the experimental protocol (Table 
1).
3. Experimental animals
Ninety-six Wister rats weighing about 150 g each were 
purchased from the animal house of Obafemi Awolowo 
University, Ile-Ife, Nigeria. The rats were randomly arranged 
in separate wooden cages (16 per group; 2 replicates of 8 
each) and were allowed to acclimatize for 7 days before 
commencement of the experiment. The room temperature 
in the animal house was 28±2
oC and a 12-hr light/dark cycle 
was employed. The rats were handled following standard 
ethical procedures.Korean J Hematol 2012;47:67-73.
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4. Experimental (control) diet
The commercial (control) diet for the rats was purchased 
from the animal house of the Ladoke Akintola University 
of Technology, Osogbo, Nigeria. The rats were fed rat pellets 
and water ad libitum.
5. Leukemia induction
Leukemia was successfully induced in Wister rats by intra-
venous injection of 0.2 mL of a 1：10 diluted benzene sol-
ution (Chromasolv, in water/2-propanol [50/50] v/v), given 
every 2 days for 3 consecutive weeks. The aqueous solution 
of the mushroom metabolites (20 mg/mL) produced by submerg-
ed fermentation was orally administered by gavage (0.2 mL) 
before, during, and after leukemia induction. Leukemia bur-
den was assessed by comparing the hematological parameters 
at baseline and after leukemia induction in various ex-
perimental groups (Table 1).
6. Blood samples analysis
After 3 weeks of benzene injection and administration 
of metabolites (as designed in the experimental protocol), 
animals in the respective groups were bled by cardiac 
puncture. The blood was collected into ethylenediamin-
etetraacetic acid (EDTA) vials, gently mixed, labeled, and 
analyzed. The animals were handled and killed ethically 
as recommended by animal care regulations.
7. Estimation of hematological parameters and indices
Hematological parameters and indices were assessed by 
flow cytometry (direct current method) using suitable cell 
packs according to the manufacturer’s specification for the 
desired cell population on the SYMEX KX-21N autoanalyzer.
8. Differential WBC count
The Leishman staining technique was used to compliment 
the automation estimation result. The technique was applied 
as previously described [6]. The stained slides were allowed 
to dry and examined using the battlement method with 
an oil immersion objective (×100). One hundred consecutive 
leukocytes indicating various types encountered were count-
ed and recorded.
9. Determination of immunomodulatory functions of the me-
tabolites
Leukocytes comprise of macrophages and NK cells have 
been shown to play important roles in cancer surveillance 
in the human body and subsequently elimination of cancer-
ous cells [3]. In order to determine the immunomodulatory 
functions of the metabolites, their potential to enhance bone 
marrow leukopoiesis was determined on the basis of the 
total leukocyte count and phagocytic function of WBCs as 
measured using the carbon clearance test described below.
The rats were divided into 4 groups of 8 animals in each 
group, received various treatments as mentioned below, and 
were used for the above-described assays.
The characteristics of the groups were as follows: group 
1: control (normal) rats were given only normal saline, while 
rats in groups 2, 3, and 4 received doses of 20 mg/mL, 40 
mg/mL, and 80 mg/mL, respectively. All solutions were ad-
ministered using an oral cannula, once per day for 8 days.
10. Enhancement of leukopoiesis
The leukocytes were counted as previously described [7]. 
Blood samples were collected into EDTA anticoagulant vials 
through the tail of Wister rats on the 8
th day of metabolite 
administration. The blood (20 μL) was diluted in 0.38 mL 
of Turk’s solution and the suspension was charged onto the 
new improved Neubauer counting chamber. The cells were 
counted microscopically using a 16-mm eyepiece and a ×10 
objective.
11. Determination of phagocytic activity
The phagocytic activity of the reticuloendothelial system 
(RES) was assessed by using the carbon clearance method 
[8]. Briefly, 1 mL of Indian ink was administered intra-
venously to all 4 groups of adult Wister rats on the 8
th 
day of metabolite administration. Blood samples were col-
lected at 3-, 6-, 9-, and 12-min intervals and transferred 
directly into the centrifuge tube, allowed to coagulate at 
room temperature, and centrifuged at 2,000 rpm for 10 min. 
Then, 50 μL of clear supernatant (serum) was collected and 
transferred to different volumetric flask. The volume was 
made up to 25 mL using distilled water; absorbance was 
measured at 650 nm using a spectrophotometer. The recorded 
absorbance was plotted against time. The slope of the graph 
denotes the rate of carbon clearance, which is a measure 
of phagocytic activity of the RES and termed phagocytic 
index [9].
12. Statistical analysis
Data were analyzed using ANOVA and paired t-test. They 
are expressed as mean±SD and were pictographically ana-
lyzed using the Statistical Package for the Social Sciences 
(SPSS) version 16.
RESULTS
Results of the hematological parameters (which are the 
major leukemia indices) in the various experimental groups 
treated with P. pulmonarius and P. ostreatus metabolites 
are shown in Tables 2 and 3 and Figs. 1 and 2, respectively. 
The Tables and Figs show the statistical comparisons of vari-
ous hematological parameters between baseline and 
post-treatment of the respective experimental groups.
Group A showed a slight decrease in packed cell volume 
(PCV) when the baseline results were compared with their 
respective post-treatment values. PCV is a measure of the 
volume of RBCs compared to the total volume of blood 
and is a reliable indication of the amount of circulating 
RBCs and the degree of anemia or polycythemia in the ex-
perimental rats. A similar decrease was observed in the PCV 
of groups B and C, when their baseline and post-treatment 
values were compared (Tables 2 and 3, respectively).Korean J Hematol 2012;47:67-73.
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Fig. 1. Comparison of hematological parameters after treatment with 
Pleurotus pulmonarius metabolites between the positive control group
(E) and the other treatment groups.
Fig. 2. Comparison of the hematological parameters after treatment 
with  Pleurotus ostreatus metabolites between the positive control 
group (E) and the other treatment groups.
Fig. 3. Effect of Pleurotus ostreatus metabolites on leukocyte pro-
duction. 
Fig. 4. Effect of Pleurotus pulmonarius metabolites on leukocyte 
production. 
Groups D and F were found to have a normal PCV. Results 
of various hematological parameters in group D revealed 
that there was no adverse reaction or toxicity experienced 
by the rats as a result of administration of the 2 metabolites.
Groups A, B, C, and D were found to have a slight and 
insignificant increase in WBC counts, when their baseline 
values were compared with their post-treatment values, but 
WBC count in group E markedly increased, when the base-
line leukocyte counts were compared with the post-treat-
ment counts, which was an indication of successfully-in-
duced leukemia.
The erythrocyte counts in groups A and C were found 
to have increased, when their baseline value were compared 
with the post-treatment values. A similar increase was ob-
served in the PCV of group D showing non-toxicity of the 
metabolites. The healthy animals treated with P. ostreatus 
and P. pulmonarius metabolites presented in group D showed 
no significant alterations in erythrocyte counts, leukocyte 
counts, and hematological indices, when compared with the 
healthy animals in group F who received commercial feed 
and water only.
The total WBC (TWBC) counts in the control group served 
as reference values. In animals treated with P. ostreatus 
and P. pulmonarius metabolites, the number of leukocytes 
increased. The highest count was obtained from the animal 
group fed with metabolites at the highest dose (80 mg/mL) 
(P＜0.001) (Fig. 3 and 4). There was a statistically significant 
increase (P＜0.05) in the leukocyte counts among the treat-
ment groups (Table 4).
The results presented in Figs. 3 and 4 (P. ostreatus and 
P. pulmonarius, respectively) show that the concentration 
of carbon ink obtained after 12 min of experimental time 
decreased compared with the initially recorded value (at 
3 min). Comparatively, P. pulmonarius metabolites with 
mean phagocytic indices of 2.26, 2.03, and 1.97, respectively, 
demonstrated a significantly better phagocytic activity than 
P. ostreatus ( P＜0.05), as shown in Table 5.Korean J Hematol 2012;47:67-73.
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Table 4. Comparison of the effect of P. ostreatus and P. pulmonarius metabolites on leukopoiesis (total WBC count/mL, mean±SD).
Group Concentration of metabolites (mg/mL) Pleurotus ostreatus  P. pulmonarius  P
1 - 6,285±250.02   7,505±320 -
2 20 9,375±613.05 11,250±402.08 0.09
3 40 11,100±828.65 13,200±294.39   0.253
4 80 13,100±285.12 16,050±129.10   0.001
Table 5. Comparison of phagocytic activity of P. ostreatus and P. pulmonarius metabolites using the carbon clearance assay.
Group (concentration of metabolites) Time (mins) Pleurotus ostreatus Pleurotus pulmonarius P
2 (20 mg/mL) 3 50.13±0.85 70.13±0.85 ＜0.05
6 55.69±0.93 75.65±0.94 ＜0.05
9 59.9±1.41 79.99±1.41 ＜0.05
12 61.34±0.69 81.34±0.69 ＜0.05
3 (40 mg/mL) 3 44.85±1.20 64.85±1.20 ＜0.05
6 46.65±0.71 66.65±0.71 ＜0.05
9 50.15±0.82 70.15±0.82 ＜0.05
12 53.85±0.75 73.85±0.75 ＜0.05
4 (80 mg/mL) 3 43.40±0.29 63.40±0.29 ＜0.05
6 44.50±0.77 64.50±0.77 ＜0.05
9 47.63±0.45 67.63±0.45 ＜0.05
12 52.75±0.59 72.75±0.59 ＜0.05
DISCUSSION
In this study, anemia of chronic disease was observed 
in animals of groups A, B, and C where leukemia was induced 
due to exposure to a potent carcinogen [10]. A significant 
increase was observed in the hemoglobin concentration and 
number of erythrocytes in groups A, B, and C, when com-
pared with the leukemia-positive group (Fig. 1 and 2). This 
observation suggests that the metabolites of P. pulmonarius 
and P. ostreatus have beneficial effects on anemia in animals 
with leukemia. This finding is supported by the report on 
the hematological and metabolic effects of dietary supple-
mentation with the fungus Agaricus sylvaticus on rats bearing 
solid Walker 256 tumors [10].
Leukocytosis was observed in the groups of leukemia-in-
duced rats as demonstrated in some other works [11, 12]. 
There was a significant difference in WBCs between group 
C and group E. Leukocytosis is usually associated with leuke-
mia and was found to be restored or prevented in rats treated 
with either of the metabolites before, during, or after ex-
posure to the leukemia-inducing agent because there was 
no significant difference in the post-treatment WBC counts 
of groups A, B, and C. This was an indication of the prophy-
lactic potentials of the metabolites (Table 2 and 3).
The result was corroborated by the report of a previous 
work when the metabolites from the same organisms ex-
hibited profound antitumor activities on N-nitroso-N-ethyl-
urea-induced tumors in experimental animals [13]. The anti-
tumor activity could be attributed to fungal polysaccharide 
complexes that are capable of stimulating the non-specific 
immune system and exert antitumor activity through activa-
tion of the host’s defense mechanism [14].
In this work, we also report the immunomodulatory activ-
ity of the investigated metabolites using leukopoiesis en-
hancement and carbon clearance tests. Findings on leukopoi-
esis enhancement potential from this study showed that me-
tabolites of P. ostreatus and P. pulmonarius have the ability 
to increase the total leukocyte count in Wister rats; the 
highest count was observed in the group that received the 
highest dose (80 mg/mL). There was a significant difference 
between the groups (P＜0.005) (Table 4). This result is in 
line with the research carried out by Jain and colleagues 
[15]. They investigated the immunomodulatory activity of 
a methanolic extract of Tephrosia purpurea on the 8
th day 
of administration. The extract caused a dose-dependent increa-
se in the leukocyte count at doses of 100, 200, and 400 mL/kg 
body weight.
The carbon clearance test was employed to evaluate the 
effect of the fungal metabolites on the RES. The result ob-
tained from this research implies that administration of both 
metabolites resulted in an increased number and enhanced 
phagocytic activity of macrophages on the 8
th day of 
administration. The highest values were observed in the 
group treated with the highest dose (80 mg/mL); thus, the 
function of the macrophages was significantly enhanced. 
This was further supported by the significant increase in 
carbon clearance at a higher dose of the metabolites (80 
mg/mL), which indicates stimulation of the RES [16]. 
However, this result is in contrast to that obtained when 
the immunomodulatory activity of a polyherbal drug was 
studied [17]. Mice were fed with the respective drugs orally Korean J Hematol 2012;47:67-73.
Antileukemic effect of fungi metabolites 73
for 5 days; at 48 h after the last treatment, mice were injected 
with a carbon ink suspension (0.01 mL) via the tail vein. 
The result revealed that the rate of clearance of carbon par-
ticles was increased by all treatments when compared to 
the vehicle, but the increase was only significant at a higher 
dose of the polyherbal formulation (90 mg/kg) and not at 
a lower dose (45 mg/kg) as well as the standard levamisole 
(25 mg/kg).
In conclusion, the fungal metabolites investigated in this 
study exhibited therapeutic potential as demonstrated by 
their ability to suppress leukemia in animals following oral 
administration in various experimental groups. The bioactive 
compounds from both local and exotic mushrooms revealed 
profound immunotherapeutic and leukemia suppressor acti-
vities.
ACKNOWLEDGEMENTS
The authors thank the authority of LAUTECH, Ogbomoso, 
Nigeria, for providing some of the facilities used in these 
studies. We also appreciate the technical assistance provided 
by Olaniran O. I. and Adegoke O. of the Pharmacology 
Department and College animal house, respectively, as well 
as the support by our research assistants and undergraduate 
students.
REFERENCES
1. Wasser SP, Weis AL. Medicinal properties of substances occurring 
in higher basidiomycetes mushrooms: current perspectives. Int J 
Med Mushrooms 1999;1:31-62.
2. Kasper DL, Braunwald E, Fauci AS, et al, eds. Harrison's principles 
of internal medicine. 16th ed. New York, NY: McGraw-Hill, 
2005:333-9.
3. Petrova RD, Mahajna J, Reznick AZ, Wasser SP, Denchev CM, 
Nevo E. Fungal substances as modulators of NF-kappaB activation 
pathway. Mol Biol Rep 2008;34:145-54.
4. Reshetnikov SV, Wasser SP, Tan KK. Higher basidiomycota as a 
source of antitumor and immunostimulating polysaccharides 
(review). Int J Med Mushrooms 2001;3:361-94.
5. Soden DM, Dobson AD. Differential regulation of laccase gene 
expression in Pleurotus sajor-caju. Microbiology 2001;147:1755- 
63.
6. Bain BJ, Lewis SM. Preparation and staining methods for blood and 
bone marrow films. In: Lewis SM, Bain BJ, Bates I, eds. Practical 
haematology. 10th ed. Philadelphia, PA: Churchill Livingstone, 
2006:59-76.
7. Cheesbrough M, ed. District laboratory practice in Tropical 
Countries, part 2. Cambridge low price ed. Cambridge, UK: 
Cambridge University press, 2000:314-5.
8. Hudson L, Hay FC, eds. Practical immunology. 2nd ed. London, 
UK: Blackwell Scientific Publications, 1980:73.
9. Pallabi D, Dasgupta SC, Gomes A. Immunopotentiating and 
immunoprophylactic activities of immune-21, a polyherbal 
product. Indian J Pharmacol 1998;30:163-8.
10. Taveira VC, Novaes MR, Dos Anjos Reis M, da Silva MF. 
Hematologic and metabolic effects of dietary supplementation 
with Agaricus sylvaticus fungi on rats bearing solid walker 256 
tumor. Exp Biol Med 2008;233:1341-7.
11. Quemener V, Bansard JY, Delamaire M, et al. Red blood cell 
polyamines, anaemia and tumour growth in the rat. Eur J Cancer 
1996;32A:316-21.
12. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of 
patients with cancer contain high levels of vascular endothelial 
growth factor. Clin Cancer Res 1999;5:487-91.
13. Akanni EO, Oloke JK, Adebayo EA, Ola IO. Antitumour activities 
of Pleurotus pulmonarius and Pleurotus ostreatus metabolites on 
N-Nitroso-N-ethylurea induced solid tumour bearing Wister rats. 
J Pharm Pharm Res 2010;1:13-8.
14. A Ajith T, K Janardhanan K. Indian medicinal mushrooms as a 
source of antioxidant and antitumor agents. J Clin Biochem Nutr 
2007;40:157-62.
15. Jain V, Jat RC, Dubey S, Bhardwaj S, Jain S. Immunomodulatory 
effect of aerial part of Tephrosia purpurea (Linn). J Pharm Res 
2010;3:156-8.
16. Selvi KS, Suthanthirarajan N, Namasivayam A. Reticuloendo-
thelial function in acute noise stress. Indian J Physiol Pharmacol 
1992;36:279-81.
17. Razdan R, Roy SM. Study of the immunomodulatory activity of 
a polyherbal drug. Pharmacologyonline 2008;3:336-45.